Core Viewpoint - Oscar Health is positioned as a contrarian investment opportunity in the health insurance sector, demonstrating strong growth and profitability, particularly in light of potential regulatory changes that could expand its market significantly [1][15]. Company Overview and Q1 2025 Performance - Oscar Health is a tech-native health insurer focusing on individual and family plans through ACA exchanges, currently operating in 18 states and insuring approximately 2 million members, representing about 1 in every 13 ACA enrollees nationwide [4]. - In Q1 2025, Oscar reported $275.3 million in net income, a significant increase from $177.4 million a year prior, with total revenue reaching $3.05 billion, reflecting a robust 42% year-over-year growth [5]. - The company achieved a record-low SG&A ratio of 15.8%, down from 18.4%, indicating improved operational efficiency under new leadership [6]. Market Opportunity Analysis - The introduction of the Choose Medicare Act proposes a Medicare Part E public option, which could significantly increase Oscar's addressable market, potentially tripling it if the legislation passes [10]. - Oscar's digital infrastructure and technology position it well to capitalize on the expected influx of consumers seeking coverage through public marketplaces [10]. Valuation Discussion - Oscar trades at 14 times projected 2027 earnings, which is considered a bargain given its high double-digit revenue growth [11]. - The company's market cap of $4.8 billion is less than 50% of its current annual revenue, suggesting a valuation disconnect compared to traditional insurers [11]. Investment Considerations - The risk-reward profile favors buyers, with the potential for Oscar's valuation to increase significantly if the public option is realized, transforming it from a $5 billion to a $15 billion company within 18 months [13]. - Even without the Medicare Part E, Oscar's compelling growth metrics and operational improvements make it an attractive investment opportunity [13][15]. - The market currently undervalues Oscar as a traditional insurer, while it operates as a technology company in the insurance space, creating a unique investment opportunity [14].

In this video, I will cover Oscar Health (OSCR 16.70%) and why I find this a compelling investment opportunity. Watch the short video to learn more, consider subscribing, and click the special offer link below.*Stock prices used were from the trading day of June 17, 2025. The video was published on June 17, 2025. ...

Group 1 - Oscar Health (NYSE: OSCR) was initially rated as a "Buy" in March 2025, with the stock price falling to $12 before recovering to the $16 range [1] - MMMT Wealth, managed by Oliver, focuses on investment strategies and stock analysis, leveraging insights from investor calls, presentations, and financials [1] - Oliver has 5 years of investing experience and 4 years as a CPA, emphasizing the importance of thorough research in identifying high-potential businesses [1]

Company Overview - Oscar Health, Inc. (OSCR) shares increased by 7.8% to close at $16.11, following a significant volume of trading, contrasting with a 14.7% loss over the previous four weeks [1] - The company is positioned to capitalize on a substantial opportunity in the healthcare market, as approximately 12% of household income is spent on employer-sponsored health plans [2] Growth Strategy - Oscar's growth strategy focuses on building sustainable and scalable operations, enhancing member experience, advancing technology, and introducing innovative offerings to expand its market presence [3] Financial Performance Expectations - The upcoming quarterly earnings report is expected to show earnings of $0.34 per share, reflecting a year-over-year increase of 70%, with revenues projected at $2.86 billion, a 29% increase from the same quarter last year [4] - However, the consensus EPS estimate has been revised 0.7% lower in the last 30 days, indicating a potential negative trend in earnings estimate revisions [5] Industry Context - Oscar Health is part of the Zacks Insurance - Multi line industry, which includes other companies like MBIA (MBI), that has seen a decline of 6.7% over the past month [6] - MBIA's EPS estimate for the upcoming report remains unchanged at -$0.08, representing a 97.2% change from the previous year [7]

Core Insights - Hims & Hers Health has seen a significant increase in share price, up 138% in 2025, contrasting with other major healthcare stocks that have not performed as well [3][2] - Oscar Health is positioned as a potential multibagger in the healthcare sector, drawing comparisons to Hims & Hers due to its technology-first approach in transforming access to health insurance [4][9] Company Overview - Hims & Hers focuses on telemedicine services, appealing to younger demographics by providing convenient access to healthcare [6][7] - Oscar Health targets Affordable Care Act (ACA) members and small employers, aiming to leverage a tech-first digital platform to enhance customer acquisition [10][9] Financial Performance - Oscar Health has shown strong revenue growth over the past five years, with rising cash flow and liquidity, indicating a solid financial profile despite competition [12] - The total addressable market (TAM) for Oscar could expand from $160 billion to $720 billion by targeting individual coverage health reimbursement arrangements (ICHRAs) with small and medium-sized businesses [16] Market Position and Strategy - Oscar Health's market capitalization is approximately $4 billion, which is aligned with its cash balance, suggesting that the market may undervalue its insurance business [17] - The company is diversifying its revenue streams to mitigate risks associated with potential regulatory changes affecting the ACA [14][19] Investment Outlook - There are potential near-term challenges for Oscar Health, but the long-term vision is seen as compelling, with expectations for significant share price appreciation similar to Hims & Hers [19][18]

Group 1 - The focus is on growth and dividend income, with a strategy aimed at creating a portfolio that emphasizes compounding dividend income and growth [1] - The portfolio is structured to provide monthly dividend income that increases through dividend reinvestment and annual raises [1] Group 2 - There is an intention to potentially start a position in OSCR in the near future [2] - The article serves as personal opinion and is not intended as a recommendation for stock purchase or sale [2] Group 3 - Past performance is not indicative of future results, and no specific investment advice is provided [3] - The views expressed may not represent those of Seeking Alpha as a whole, and the analysts may not be licensed or certified [3]

Group 1 - Healthcare stocks in the U.S. are experiencing pressure due to increasing regulatory headwinds and rising costs [1]

I am rating Oscar Health, Inc. (NYSE: OSCR ) as a hold due to a proposed steep budget cut of $163 billion in the 2026 budget estimates. The Health and Human Services (HHS) cut is estimated to be $33.3 billion, an $18 billion cutFirst Principles Partners is an equity research analyst specializing in technology, innovation, and sustainability investment. My unique approach, "First Principles," involves breaking down complex problems to their most basic elements in terms of financial and technology, enabling m ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________to__________ Commission File Number: 001-40154 Oscar Health, Inc. (Exact name of registrant as specified in its charter) Delaware 46-1315 ...

Financial Data and Key Metrics Changes - The company reported total revenue of $3 billion for the quarter, a 42% increase year over year [6] - Net income was approximately $275 million, a significant improvement of $98 million over the prior year period [7][22] - Earnings from operations grew by $112 million to $297 million, with an operating margin of 9.8%, an increase of 110 basis points year over year [8][21] - The medical loss ratio (MLR) increased by 120 basis points year over year to 75.4% [8][18] - The selling, general and administrative (SG&A) expense ratio improved to 15.8%, a 260 basis point improvement year over year, marking the lowest in the company's history [8][20] Business Line Data and Key Metrics Changes - The company closed the quarter with approximately 2 million effectuated members, a 41% increase year over year [9][16] - Membership growth was driven by strong retention and above-market growth during open enrollment [16] - The company launched Oscar Community Resources with Find Help, enhancing member services beyond medical care [10] Market Data and Key Metrics Changes - The company noted that the individual market is a cornerstone of American healthcare, driving a record low uninsured rate [13] - The proposed program integrity initiatives by CMS are seen as positive for the long-term sustainability of the market, although the shortened enrollment window may constrain shopping for plans [12][51] Company Strategy and Development Direction - The company aims to deepen market presence through new partnerships and innovative plan designs [10][14] - The focus remains on building a scalable and efficient technology infrastructure to enhance member experience and operational efficiency [11] - The company is engaged with policymakers to advocate for solutions that strengthen the individual market [13] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving 2025 targets due to disciplined execution and strong top-line growth [14][24] - The company anticipates membership trends to rise in the first half of the year but expects a decline in the latter half due to regulatory changes [31] - Management highlighted the importance of a trustworthy market and the need for adequate time for individuals to shop for plans [51] Other Important Information - The company reaffirmed its full-year guidance metrics, expecting total revenue in the range of $11.2 billion to $11.3 billion for 2025 [23][24] - Adjusted EBITDA for the quarter was $329 million, reflecting a substantial year-over-year improvement [22] Q&A Session Summary Question: Membership expectations for the second quarter and the rest of the year - Management expects membership to trend up in the first half of the year but to decline in the latter half due to regulatory changes [31][32] Question: Grace period membership context and its impact on MLR - Management indicated that the gap between effectuated and paid membership is expected to normalize, with prior period development impacting MLR [36][38] Question: Utilization patterns between new and retired members - Management noted higher inpatient utilization with favorable pharmacy trends, but specific drivers were not identified [42] Question: Thoughts on competitor exits and their impact on risk adjustment - Management views competitor exits as an opportunity, emphasizing disciplined pricing and effective risk adjustment [46][62] Question: Regulatory environment and potential impacts on enrollment - Management supports CMS efforts to strengthen ACA integrity but expressed concerns about the shortened enrollment period affecting consumer choice [51] Question: Expectations for risk adjustment as a percentage of premiums - Management does not anticipate significant adjustments to risk adjustment percentages at this time, but elevated claims could impact future expectations [64] Question: Drivers of SG&A performance and future expectations - Management attributed SG&A improvements to fixed cost leverage, variable cost efficiencies, and lower exchange fees, with expectations for gradual increases moving forward [74][75]